Rhythm Phase 3 EMANATE trial of setmelanotide fails primary BMI endpoints
Rhythm Pharmaceuticals' Phase 3 EMANATE trial of setmelanotide fails primary BMI endpoints across four genetic obesity substudies
- Post hoc analyses showed significant BMI reductions in POMC/PCSK1 heterozygous patients in the EMANATE trial.
- Post hoc analyses also found significant BMI reductions in SRC1 heterozygous patients treated with setmelanotide.
- Rhythm Pharmaceuticals is evaluating next-step development paths for setmelanotide following the EMANATE Phase 3 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.